Real-world first-line treatment of patients with BRAF(V600E)-mutant metastatic colorectal cancer: the CAPSTAN CRC study

BACKGROUND: BRAF(V600E) mutations occur in 8%-12% of metastatic colorectal cancer (mCRC) cases and are associated with poor survival. European guidelines recommend combination (doublet or triplet) chemotherapy plus bevacizumab in first line. However, an unmet need remains for more effective treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinelli, E., Cremolini, C., Mazard, T., Vidal, J., Virchow, I., Tougeron, D., Cuyle, P.-J., Chibaudel, B., Kim, S., Ghanem, I., Asselain, B., Castagné, C., Zkik, A., Khan, S., Arnold, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832736/
https://www.ncbi.nlm.nih.gov/pubmed/36368253
http://dx.doi.org/10.1016/j.esmoop.2022.100603

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832736/
https://www.ncbi.nlm.nih.gov/pubmed/36368253
http://dx.doi.org/10.1016/j.esmoop.2022.100603

Ejemplares similares